CIAM
HRTX icon

Caitong International Asset Management’s Heron Therapeutics HRTX Stock Holding History

Caitong International Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Sell
1
-35,105
-100% -$40.7K ﹤0.01% 2481
2025
Q4 		$45.6K Buy
35,106
+27,040
+335% +$33.4K 0.01% 739
2025
Q3 		$10.2K Buy
8,066
+5,885
+270% +$9.33K 0.01% 1011
2025
Q2 		$4.51K Sell
2,181
-657
-23% -$1.34K ﹤0.01% 1059
2025
Q1 		$6.24K Buy
2,838
+2,208
+350% +$4.29K ﹤0.01% 969
2024
Q4 		$964 Buy
+630
New +$1.02K ﹤0.01% 1334

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Caitong International Asset Management's HRTX Position: Q1 2026 in Review

Caitong International Asset Management reduced its Heron Therapeutics (HRTX) stake by 100% in Q1 2026, selling an estimated $40.7K and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #2481.

Caitong International Asset Management first reported a position in HRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $45.6K in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Caitong International Asset Management held 1 share of Heron Therapeutics worth $1 as of Q1 2026.
  • Caitong International Asset Management sold 35,105 Heron Therapeutics shares in Q1 2026, an estimated $40.7K.
  • Heron Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2481 holding.
  • Caitong International Asset Management first reported a position in Heron Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Caitong International Asset Management's Heron Therapeutics position peaked at $45.6K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.